Cargando…
Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
The development of a vaccine against human immunodeficiency virus-1 (HIV-1) capable of inducing broad humoral and cellular responses at both the systemic and mucosal levels will be critical for combating the global AIDS epidemic. We previously demonstrated the ability of Newcastle disease virus (NDV...
Autores principales: | Khattar, Sunil K., Samal, Sweety, LaBranche, Celia C., Montefiori, David C., Collins, Peter L., Samal, Siba K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788131/ https://www.ncbi.nlm.nih.gov/pubmed/24098600 http://dx.doi.org/10.1371/journal.pone.0078521 |
Ejemplares similares
-
Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014) -
Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
Publicado: (2020) -
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017) -
Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus
por: Manoharan, Vinoth K., et al.
Publicado: (2018) -
Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Khattar, Sunil K., et al.
Publicado: (2015)